Ignore the noise of the daily prices, particularly in a volatile market.
If IHL-42X becomes a genuine drug for OSA then IHL will be valued according to that market opportunity and Resmed demonstrates what that’s potentially worth. Even if IHL captured a modest percentage of their market share it’s billions. Many billions.
And that’s just one of six indications being developed.